Maze Therapeutics Insider: CBO Dandekar Buys Low, Sells High – A Rule‑Based Rally Amid Volatility

Insider Activity Highlights Maze Therapeutics’ Recent Moves

In a routine yet telling series of Form 4 filings, Maze Therapeutics’ executive Atul Dandekar (Chief Strategic Business Officer) has continued to adjust his stake through a Rule 10b‑5‑1 trading plan. On March 30, 2026 he bought 7,500 shares at $10.42 and simultaneously sold 6,710 shares at an average of $29.26, followed by an additional 790‑share sale at $30.02. These trades, executed under a pre‑arranged plan adopted September 29, 2025, signal a balanced approach: Dandekar is both adding to his position and realizing gains as the stock has surged to $29.85.

What Investors Should Note

The net result of Dandekar’s March 30 activity is a modest net purchase of 7,500 shares, reflecting confidence that the stock’s price trajectory will continue upward. The fact that he is buying at a price roughly 35% below the current market level suggests he views the shares as undervalued, especially given Maze’s 52‑week low of $6.71 and a market cap of $1.51 B. Moreover, Dandekar’s historic pattern shows a preference for buying when prices dip (e.g., the 100‑share purchase at $10.42 in late December) and selling when the stock climbs (e.g., the 66,365‑share sale at $40.51). This disciplined, rule‑based trading lends credence to the idea that he is positioning himself for long‑term upside rather than chasing short‑term gains.

Implications for Maze’s Future

The insider activity occurs against a backdrop of mixed market sentiment: the stock has fallen 40.8% over the past week and 36.4% monthly, yet the year‑to‑date gain of 211% indicates a strong rally. Dandekar’s buying amid a volatile period could be interpreted as a bullish signal, especially given that other insiders—such as President R&D & CMO Harold Bernstein—have also been active, both buying and selling in large tranches. For investors, this suggests that Maze’s leadership remains committed to the company’s long‑term strategy, even as the share price experiences short‑term swings. The steady flow of insider purchases may support the stock’s recovery, countering any bearish sentiment that has emerged from the recent 40% weekly decline.

A Closer Look at Dandekar Atul (CSBO)

Dandekar’s transaction history is marked by consistency and adherence to pre‑planned trading windows. Since the start of 2026, he has executed multiple 7,500‑share purchases at $10.42 and sold significant blocks when the price rose above $40, often timing sales to coincide with a Rule 10b‑5‑1 window. His activity peaked in late December 2025 with a 72,400‑share purchase at $10.42, followed by a 66,365‑share sale at $40.51, illustrating a clear “buy low, sell high” strategy. Importantly, all trades are disclosed in advance, mitigating the risk of market perception of insider abuse. This disciplined approach is a positive signal to shareholders and may reinforce investor confidence in the company’s governance and long‑term prospects.

Bottom Line

While Maze Therapeutics’ shares have endured a sharp weekly decline, insider activity—particularly from Dandekar—shows a measured and rule‑based buying stance. Coupled with the company’s recent performance and strong year‑to‑date gains, the insider transactions suggest that the leadership remains optimistic about Maze’s trajectory. Investors should view Dandekar’s recent purchases as a bullish endorsement of the stock’s intrinsic value, while also monitoring the broader market dynamics that may influence short‑term price movements.